Innate Pharma (IPHA) Reports FY22, Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Innate Pharma (IPHA) Reports FY22, Provides Business Update

Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update

March 23, 2023 2:00 AM EDT

Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET® program and two additional targets, with 25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in Sézary syndrome and mycosis fungoides First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with $50M payment from AstraZeneca Cash position of 136.6 million2 as of December 31, 2022 (not including the 25 million payment from Sanofi), anticipated cash runway into mid... More